H.C. Wainwright Keeps Their Buy Rating on Iterum Therapeutics (ITRM)

In a report released yesterday, Ed Arce from H.C. Wainwright maintained a Buy rating on Iterum Therapeutics (ITRMResearch Report), with a price target of $17.00. The company’s shares closed last Monday at $2.37, close to its 52-week low of $1.89.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 5.0% and a 33.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Conatus Pharmaceuticals.

Iterum Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $18.50, which is a 687.2% upside from current levels. In a report issued on November 13, Needham also maintained a Buy rating on the stock with a $20.00 price target.

See today’s analyst top recommended stocks >>

Based on Iterum Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $31.27 million. In comparison, last year the company had a GAAP net loss of $24.91 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents.